You are currently viewing a new version of our website. To view the old version click .
Proceedings
  • Abstract
  • Open Access

19 October 2017

Synthesis, Anticandidal Activity and Molecular Docking Study of Some New Imidazole Derivatives †

,
,
,
and
1
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, 26470 Eskişehir, Turkey
2
Doping and Narcotic Compounds Analysis Laboratory, Faculty of Pharmacy, Anadolu University, 26470 Eskişehir, Turkey
*
Author to whom correspondence should be addressed.
Presented at the 1st Molecules Medicinal Chemistry Symposium, Barcelona, Spain, 8 September 2017.
This article belongs to the Proceedings Proceedings of the 1st Molecules Medicinal Chemistry Symposium, Barcelona, Spain
The azole pharmacophore is still regarded as a viable lead structure for the synthesis of more effective antifungal agents [1,2,3]. In this study, new 2-substituted-N-[4-(1H-imidazole-1-yl) phenyl] acetamide (5a5g, 6a6n) derivatives were synthesized and the antifungal activities of these compounds were evaluated. The synthesized compounds consisted of two novel series of imidazole derivatives containing dithiocarbamate (5a5g) and (benz) azolethiol (6a6n) side chains that are structurally related to the famous antifungal azole pharmacophore. Their structures were characterized by spectral (IR, 1H NMR, 13C NMR, and MS spectra) analyses. The synthesized compounds were screened for in vitro antifungal activity against pathogenic strains of fungi. Theoretical ADME predictions were calculated for final compounds. A molecular docking study of the most active compound with target ‘lanosterol 14α-demethylase’ (CYP51) [4] was performed to unravel the mode of antifungal action.
Compound 5e, which features imidazole and 4-methoxybenzyl piperazine scaffolds, showed the most promising antifungal activity with a MIC50 value of 0.78 ug/mL against Candida krusei. The effect of the compound 5e against ergosterol biosynthesis was observed by the LC-MS-MS method, which is based on quantification of the ergosterol level in C. krusei. Significant interactions were also observed between compound 5e and 14-α-sterol demethylase. In addition to good antifungal activity, all compounds in the series exhibited a good predicted pharmacokinetics profile.

Acknowledgments

This study was financially supported by Anadolu University Scientific Projects Fund, Project No.: 1705S312.

Author Contributions

Y.Ö. conceived and designed the experiments; A.I. and U.A.C. performed the synthesis; S.L. performed analysis studies; B.N.S. performed activity tests; B.N.S. performed docking studies; B.N.S., A.I., U.A.C., Y.Ö. and S.L. wrote the paper.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. White, T.C.; Marr, K.A.; Bowden, R.A. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 1998, 11, 382–402. [Google Scholar] [CrossRef] [PubMed]
  2. Shah, J.J.; Khedkar, V.; Coutinho, E.C.; Mohanraj, K. Design, synthesis and evaluation of benzotriazole derivatives as novel antifungal agents. Bioorg. Med. Chem. Lett. 2015, 25, 3730–3737. [Google Scholar] [CrossRef] [PubMed]
  3. Wani, M.Y.; Ahmad, A.; Shiekh, R.A.; Al-Ghamdi, K.J.; Sobral, A.J. Imidazole clubbed 1,3,4-oxadiazole derivatives as potential antifungal agents. Bioorg. Med. Chem. 2015, 23, 4172–4180. [Google Scholar] [CrossRef] [PubMed]
  4. Larissa, M.P.; Thomas, L.P.; Michael, R. Crystal structure of cytochrome P450 14α-sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors. PNAS 2001, 98, 3068–3073. [Google Scholar]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.